Navigation Links
Eaton Scientific Announces Clinical Trial Plans for Tropine 3 - Company to Seek FDA Approval as Novel Prescription Drug for Non-Hormonal Treatment of Hot Flashes in Menopausal Women
Date:8/28/2012

BEVERLY HILLS, Calif., Aug. 28, 2012 /PRNewswire/ -- Eaton Scientific Systems, Ltd. ("Eaton Scientific" or the "Company"), a wholly owned subsidiary of Pristine Solutions, Inc. (OTCQB: PRTN) is pleased to announce select details of its planned multi-phase multi-location clinic trials for FDA approval of its novel drug indication Tropine 3, containing currently FDA approved Homatropine, in oral an suspension.

"We are currently finalizing preparations for what we believe will be the landmark clinical studies of our novel drug indication Tropine 3 for treatment and relief of the symptoms of hot flashes in menopausal women – one of the top concerns of women's healthcare today," stated Michael Borkowski, CEO and President of Eaton Scientific.   "The Company continues to build an outstanding team of very highly accredited medical professionals to plan, manage, and conduct every step of the clinic trials which were specifically designed to test, prove, and ultimately promote the short-term efficacy and safety Tropine 3.  We anticipate that final Phase 1-2 protocol preparations and patient enrollment start dates will be confirmed shortly."

Eaton intends to conduct multiple clinical trials in Phase 1-2 & Phase 3 of Tropine 3.  The first trial is planned to be an FDA protocol approved "Phase 1-2, Prospective, Randomized, Double Blind, Placebo-Controlled, Dose Escalation, Parallel-Group Study to Test the Efficacy and Safety of Homatropine Methylbromide Oral Suspension on Selected Climacteric Symptoms and Quality of Life in Menopausal Women Not Receiving Hormonal Replacement Therapy ("HRT")".  The drug, homatropine, is an anticholinergic medication that is an antagonist at muscarinic acetylcholine receptors and thus the parasympathetic nervous system.  It is used in eye drops as a cycloplegic, and as a mydriatic in order to dilate the pupil.  Homatropine is also given as an atropine substitute given to reverse the muscarinic and CNS effects associated with indirect cholinomimetic administration.  Homatropine has been prescribed continuously and safely in the United States for over 40 years.

The Company anticipates conducting the clinic trials at multiple sites across the United States and plans to publish the results in medical journals and women's health publications.  The Company intends to begin marketing Tropine 3 to pharmaceutical companies for potential acquisition following completion of the first Phase 1-2 clinic trial.

About Pristine Solutions, Inc.

Pristine Solutions, Inc., through its wholly-owned subsidiary company, Eaton Scientific Systems, Ltd., holds the intellectual property and global marketing rights to Tropine 3, a patent pending novel indication of an existing FDA approved drug for the non-hormonal treatment of hot flashes in pre-menopausal, pari-menopausal, and post-menopausal women.

Forward-Looking Statements/Disclaimer

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Pristine Solutions' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Pristine Solutions' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Pristine Solutions herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Pristine Solutions disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.


'/>"/>
SOURCE Eaton Scientific Systems, Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eaton Scientific Systems Confirms Acquisition and Status of Tropine 3 Patent Pending Non-Hormonal Treatment of Hot Flashes in Menopausal Women
2. Pristine Solutions, Inc. Completes Acquisition of Eaton Scientific Systems, Ltd. - Enters Multi-Billion Dollar Womens Health and Drug Sector
3. Clinilabs Opens Phase I Unit In Eatontown, New Jersey
4. Kewaunee Scientific Corporation Declares Quarterly Dividend
5. Star Scientific, Inc. Files Second-Quarter Financial Report (Net Sales and Gross Profits Continue to Increase) and Updates Research and Marketing Activities
6. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
7. Sanovas Forms Scientific Advisory Board to Support Development of Lung Cancer Technology
8. Boston Scientific Announces Promising Clinical Data on New Products at the International Spine Intervention Society 20th Annual Scientific Meeting
9. Boston Scientific to Announce Second-Quarter 2012 Financial Results on July 26
10. Pappas Ventures Names Pat Gage to Scientific Advisory Board
11. Boston Scientific Completes Patient Enrollment in PREVAIL Study for First-in-Class WATCHMAN Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
(Date:12/7/2016)... FRANCISCO , December 7, 2016 ... expected to reach a value of USD 3.9 ... by Grand View Research, Inc. The growth of ... of donor and continuous technological advancements by the ... increasing continuously due to increasing donation, rising awareness ...
(Date:12/6/2016)... -- Diabetes & Obesity Drug Development Pipeline Review, 2016 ... is currently dominated by therapeutics indicated for type 1 ... and the majority of the pipeline, in terms of ... these indications. While products indicated for obesity do not ... large number of these products in the pipeline, with ...
Breaking Medicine Technology:
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
(Date:12/7/2016)... ... 2016 , ... The medical profession is well aware that heart attacks do ... analyzing heart attacks among 138,602 people recorded a 35% higher number of heart attacks ... agree of course–no time of year is a good time for a heart attack! ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare professionals to ... WellnessPro platform by expanding the treatment modalities available in a single device. ...
(Date:12/7/2016)... ... 07, 2016 , ... “Tomorrow Trump Goes To Washington”: a brief but ... presidency and to America. “Tomorrow Trump Goes To Washington” is the creation of published ... for this country. , Nancy attributes her patriotic nature to her WWII veteran father. ...
Breaking Medicine News(10 mins):